BioMarin Announces that Phase 3 Cohort of Valoctocogene Roxaparvovec, Gene Therapy Study in Severe Hemophilia A Met Pre-Specified Criteria for Regulatory Submissions in the U.S. and Europe

Timing of Regulatory Submissions to Be Determined in 3Q 2019 Conference Call and Webcast to be Held Tuesday, May 28, 2019 at 8:00 AM Eastern SAN RAFAEL, Calif., May 28, 2019 -- (Healthcare Sales & Marketing Network) -- BioMarin Pharmaceutical Inc. (... Biopharmaceuticals BioMarin Pharmaceutical, valoctocogene roxaparvovec, hemophilia A, gene therapy
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news